Genomic testing for germline predisposition to hematologic malignancies

Blood Res. 2024 Mar 8;59(1):12. doi: 10.1007/s44313-024-00012-y.ABSTRACTGermline predisposition (GPD) to hematological malignancies has gained interest because of the increased use of genetic testing in this field. Recent studies have suggested that GPD is underrecognized and requires appropriate genomic testing for an accurate diagnosis. Identification of GPD significantly affects patient management and has diverse implications for family members. This review discusses the reasons for testing GPD in hematologic malignancies and explores the considerations necessary for appropriate genomic testing. The aim is to provide insights into how these genetic insights can inform treatment strategies and genetic counseling, ultimately enhancing patient care.PMID:38485837 | PMC:PMC10923764 | DOI:10.1007/s44313-024-00012-y

Source: Blood Research - March 15, 2024 Category: Hematology Authors: Sang Mee Hwang Source Type: research